Head, Patient Insights and Advocacy
Indivior
Terry L. Horton, MD, FACP, FASAM is a member of the teaching faculty of the Department of Medicine, Attending Physician, Chief of the Division of Addiction Medicine, and Associate Physician Lead of the Behavioral Health Service Line at Christiana Care Health Services in Wilmington, Delaware. In addition to teaching medical students and residents in inpatient and outpatient medicine, he has chaired the Alcohol Withdrawal Workgroup which developed and implemented alcohol screening, treatment and referral protocols into the institution’s electronic health record, an effort recognized nationally by the AHRQ Innovation Exchange as a model effort. More recently, Dr Horton helped develop and launch the Opioid Withdrawal Pathway to screen, identify and treat opioid addicted patients who are admitted into the hospital. He has similarly developed a new Substance Abuse Consultation Liaison role assisting with the care of hospitalized patients. Dr. Horton is the founder and Medical Director of Project Engage, a nationally recognized and award winning program using peer counselors integrated into health systems to help identify and transition substance use disordered patients into ongoing drug and alcohol treatment. Dr Horton currently chairs Delaware’s new Drug Overdose Fatality Review Commission and has served on a number of similar efforts both in New York and Delaware. His interests include improving the care of hospitalized substance disordered patients as well as understanding their impact on health systems, innovating and researching methods to better integrate addiction medicine into inpatient and outpatient systems of care, and physician and student training. Dr Horton has published broadly and is a frequent speaker regionally and nationally on these topics.
Previously, Dr. Horton worked as the Medical Director and Vice President of Phoenix House Foundation in New York developing innovative models of on site primary care and the use of buprenorphine within substance abuse treatment settings. He was a member of the Clinical Trials Network of the National Institute on Drug Abuse from 2000 to 2015 participating in a number of national research efforts.
